Core Insights - Aspira Women's Health Inc. has announced a new agreement with Anthem Blue Cross for reimbursement coverage of its OvaSuiteSM portfolio of risk assessment tests, effective June 1, 2024, covering approximately six million lives in California [1][2] Company Overview - Aspira Women's Health Inc. focuses on the development of noninvasive, AI-powered diagnostic tests for gynecologic diseases [3] - The company offers OvaWatch® and Ova1Plus® as part of the OvaSuiteSM, which provides comprehensive blood tests for ovarian cancer detection [4] Product Details - OvaWatch has a negative predictive value of 99% and is used for assessing ovarian cancer risk in women with indeterminate or benign adnexal masses [4] - Ova1Plus is a reflex process involving two FDA-cleared tests to evaluate the risk of ovarian malignancy in women scheduled for surgery [4] - The company is developing additional tests, including OvaMDxSM for ovarian cancer and EndoCheckSM for endometriosis, addressing significant diagnostic needs [4] Strategic Focus - The agreement with Anthem Blue Cross is part of Aspira's strategic focus on payer adoption, which is gaining momentum following the successful completion of the credentialing process [2] - Anthem Blue Cross serves over 118 million people, with more than 45 million within its health plans, indicating a substantial market opportunity for Aspira [2]
Aspira Women's Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California